<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.1/dist/css/bootstrap.min.css" rel="stylesheet">
    <style>
        body{background-color:slategrey};
    </style>
  </head>
<body>
<div class="container" style="margin-top:20px; width:1024px">

<div class="row">
    
    <div class="col"><img style="width:310px; margin-top:10px" src="/Users/hechao/tabular/tables/acs.jmedchem.2c01287/table.001.dbg.png"/></div>
    
    <div class="col"><img style="width:310px; margin-top:10px" src="/Users/hechao/tabular/tables/acs.jmedchem.2c01287/table.003.dbg.png"/></div>
    
    <div class="col"><img style="width:310px; margin-top:10px" src="/Users/hechao/tabular/tables/acs.jmedchem.2c01287/table.007.dbg.png"/></div>
    
</div>


    <table class="table table-bordered row" width="500px">
        <tr>
            <td style="background:lightblue" colspan="6">Table 1. Structure-Activity Relationships (SAR) of C-3'-</td>
        </tr>
        
        <tr>
            
            <td>compound</td>
            
            <td>2</td>
            
            <td>19</td>
            
            <td>20</td>
            
            <td>26</td>
            
            <td>27</td>
            
        </tr>
        
        <tr>
            
            <td>R = human CD73a IC50 (nM)</td>
            
            <td>H 100 + 39d</td>
            
            <td>Me 51</td>
            
            <td>ethynyl 1.7  0.22e</td>
            
            <td>vinyl 103</td>
            
            <td>Et 200</td>
            
        </tr>
        
        <tr>
            
            <td>human Cell surfaceb IC50 (nM) human plasma CD73c IC50 (nM)</td>
            
            <td>434</td>
            
            <td>169</td>
            
            <td>2.8 + 0.41f 5.6  0.24d</td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>cLog P</td>
            
            <td>0.37</td>
            
            <td>0.15</td>
            
            <td>0.74</td>
            
            <td>0.39</td>
            
            <td>0.67</td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="6"></td>
        </tr>
    </table>
    <div class="row" style="margin-top:10px"></div>

    <table class="table table-bordered row" width="500px">
        <tr>
            <td style="background:lightblue" colspan="6">Table 3. SAR Summary of a-Alkyl Malonic Acid Analogues 34a-ja,b</td>
        </tr>
        
        <tr>
            
            <td>Compd</td>
            
            <td>R</td>
            
            <td>Human CD73 IC50 (nM)</td>
            
            <td>Compd</td>
            
            <td>R</td>
            
            <td>Human CD73 IC50 (nM)</td>
            
        </tr>
        
        <tr>
            
            <td>20</td>
            
            <td>[CCO]</td>
            
            <td>1.7 a</td>
            
            <td>34e</td>
            
            <td>[CCO]</td>
            
            <td>6 a</td>
            
        </tr>
        
        <tr>
            
            <td>31</td>
            
            <td>H</td>
            
            <td>58 b</td>
            
            <td>34f</td>
            
            <td>[CCO]</td>
            
            <td>5 a</td>
            
        </tr>
        
        <tr>
            
            <td>34a</td>
            
            <td>Et</td>
            
            <td>24 a</td>
            
            <td>34g</td>
            
            <td>[CCO]</td>
            
            <td>9 a</td>
            
        </tr>
        
        <tr>
            
            <td>34b</td>
            
            <td>Allyl</td>
            
            <td>20 a</td>
            
            <td>34h</td>
            
            <td>[CCO]</td>
            
            <td>13 a</td>
            
        </tr>
        
        <tr>
            
            <td>34c</td>
            
            <td>Propargyl</td>
            
            <td>7 b</td>
            
            <td>34i</td>
            
            <td>[CCO]</td>
            
            <td>8 a</td>
            
        </tr>
        
        <tr>
            
            <td>34d</td>
            
            <td>[CCO]</td>
            
            <td>1.8 a</td>
            
            <td>34j</td>
            
            <td>[CCO]</td>
            
            <td>4 a</td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="6">aThe inhibitory activity was evaluated against recombinant human CD73 (0.05 nM) using a malachite green assay. The inhibitory activity was. evaluated against recombinant human CD73 (0.5 nM) using a malachite green assay. A lower CD73 enzyme concentration level was applied to accurately assess the inhibitory activity of the more potent new analogues.</td>
        </tr>
    </table>
    <div class="row" style="margin-top:10px"></div>

    <table class="table table-bordered row" width="500px">
        <tr>
            <td style="background:lightblue" colspan="6">Table 7. Plasma Protein Binding Profile of 49a.</td>
        </tr>
        
        <tr>
            
            <td>plasma protein binding (% bound)</td>
            
            <td>63%</td>
            
            <td>71%</td>
            
            <td>42%</td>
            
            <td>60%</td>
            
            <td>58%</td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="6">The data were determined at 10 M concentration of 49. 0.42) is most likely responsible for the minimal loss of its. CD73 inhibitory activity in the presence of full plasma, which</td>
        </tr>
    </table>
    <div class="row" style="margin-top:10px"></div>


<div></body>
</html>